Gilder Gagnon Howe & Co’s TG Therapeutics TGTX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,393	Closed	-$608K	–	275
2025 Q4	$608K	Sell	20,393 -50,968	-71%	-$1.66M	0.01%	231
2025 Q3	$2.58M	Buy	71,361 +51	+0.1%	+$1.68K	0.03%	186
2025 Q2	$2.57M	Sell	71,310 -9,467	-12%	-$352K	0.03%	170
2025 Q1	$3.19M	Sell	80,777 -515	-0.6%	-$17.3K	0.04%	155
2024 Q4	$2.45M	Buy	81,292 +16,394	+25%	+$470K	0.03%	180
2024 Q3	$1.52M	Buy	64,898 +4,225	+7%	+$92.3K	0.02%	195
2024 Q2	$1.08M	Buy	+60,673	New	+$968K	0.01%	203

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Gilder Gagnon Howe & Co's TGTX Position: Q1 2026 in Review

Gilder Gagnon Howe & Co sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 20,393 shares — an estimated $608K sold.

Gilder Gagnon Howe & Co first reported a position in TGTX in Q2 2024 and held it in 7 quarters. The position peaked at $3.19M in Q1 2025. 365 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Gilder Gagnon Howe & Co reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 20,393 TG Therapeutics shares in Q1 2026, an estimated $608K.
Gilder Gagnon Howe & Co first reported a position in TG Therapeutics in Q2 2024 and held it in 7 quarters.
Gilder Gagnon Howe & Co's TG Therapeutics position peaked at $3.19M in Q1 2025.
365 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2026, filed 15 May 2026.